BioVie Inc. (BIVI) Financial Statements (2024 and earlier)

Company Profile

Business Address 680 W NYE LANE
CARSON CITY, NV 89703
State of Incorp. NV
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q1
6/30/2023
Q4
3/31/2023
Q3
12/31/2022
Q2
9/30/2022
Q1
6/30/2022
Q4
3/31/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19,46131,27645,74921,23118,64224,507
Cash and cash equivalents19,46131,27645,74921,23118,64224,507
Other current assets      285
Other undisclosed current assets14,58012,771241359138 
Total current assets:34,04144,04745,99021,59018,78024,792
Noncurrent Assets
Operating lease, right-of-use asset8191100109118127
Intangible assets, net (including goodwill)9831,0401,0971,1551,2121,270
Goodwill346346346346346346
Intangible assets, net (excluding goodwill)637694752809866924
Other noncurrent assets  5555 
Total noncurrent assets:1,0641,1351,2021,2691,3351,397
TOTAL ASSETS:35,10545,18347,19222,85920,11526,188
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,5255,0333,2452,6222,4433,528
Employee-related liabilities1,161
Accounts payable3,4764,8393,2452,6222,4431,206
Accrued liabilities 48194   1,161
Debt9,1056,391    
Other liabilities 481943394841,305581
Other undisclosed current liabilities1,8174,3874,213989421208
Total current liabilities:14,49516,0047,7974,0964,1694,317
Noncurrent Liabilities
Long-term debt and lease obligation5,2277,40613,26112,80212,22611,723
Long-term debt, excluding current maturities5,2277,40613,26112,72512,13911,625
Liabilities, other than long-term debt435466 48194
Other liabilities     48194
Operating lease, liability435466778798
Other undisclosed noncurrent liabilities    (77)  
Total noncurrent liabilities:5,2707,46013,32712,80212,27411,916
Total liabilities:19,76423,46421,12416,89816,44416,234
Equity
Equity, attributable to parent15,34021,71826,0685,9613,6719,955
Common stock443322
Treasury stock, value(0)(0)    
Additional paid in capital316,386313,812303,137267,344254,638252,833
Accumulated other comprehensive income 17717    
Accumulated deficit(301,226)(292,114)(277,073)(261,386)(250,970)(242,881)
Total equity:15,34021,71826,0685,9613,6719,955
TOTAL LIABILITIES AND EQUITY:35,10545,18347,19222,85920,11526,188

Income Statement (P&L) ($ in thousands)

9/30/2023
Q1
6/30/2023
Q4
3/31/2023
Q3
12/31/2022
Q2
9/30/2022
Q1
6/30/2022
Q4
3/31/2022
Q3
Revenues    2,119 
Gain (loss) on disposition of assets for financial service operations2,717(366)(3,222)(567)2,119(386)
Gross profit:    2,119 
Operating expenses(10,977)(13,775)(11,495)(8,834)(9,292)(5,749)
Other undisclosed operating income (loss) 3663,222567(2,119)386
Operating loss:(10,977)(13,775)(11,495)(8,834)(9,292)(5,749)
Interest and debt expense(1,108)(1,083)(1,053)(1,056)(927)(919)
Loss from continuing operations:(12,084)(14,857)(12,548)(9,891)(10,219)(6,667)
Loss before gain (loss) on sale of properties:(9,891)(10,219)(6,667)
Other undisclosed net income (loss)2,972(184)(3,139)(525)3,331(373)
Net loss:(9,112)(15,041)(15,687)(10,416)(6,887)(7,041)
Other undisclosed net loss attributable to parent     (1,201) 
Net loss available to common stockholders, diluted:(9,112)(15,041)(15,687)(10,416)(8,089)(7,041)

Comprehensive Income ($ in thousands)

9/30/2023
Q1
6/30/2023
Q4
3/31/2023
Q3
12/31/2022
Q2
9/30/2022
Q1
6/30/2022
Q4
3/31/2022
Q3
Net loss:(9,112)(15,041)(15,687)(10,416)(6,887)(7,041)
Other comprehensive income (loss)16017    
Comprehensive loss, net of tax, attributable to parent:(8,952)(15,025)(15,687)(10,416)(6,887)(7,041)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: